The posters include preclinical data from Surface Oncology’s two lead clinical-stage antibody therapies: SRF617 (targeting CD39) and SRF388 (targeting IL-27). Three additional posters containing preclinical data from SRF813 (targeting CD112R) and SRF231 (targeting CD47) will also be presented.
Summaries are provided below; full posters will be placed on Surface Oncology’s website following the presentation.
Details of the AACR presentations are as follows:
Presentation Type: e-poster (Abstract: 6639)
Title: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies
Lead Author:
Date and Time:
Summary:
- SRF617 is a potent inhibitor of CD39 enzymatic activity both in vitro and in vivo.
- Inhibition of CD39 potentiates the activity of chemotherapy and immunotherapy agents to improve tumor growth inhibition and survival in mice.
- Differential CD39 expression patterns across tumor types inform clinical indication selection.
- These findings support future clinical studies of SRF617 as monotherapy and in combination with other therapeutic agents in treating patients with cancer.
Presentation Type: e-poster (Abstract: 4550)
Title: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting
Lead Author:
Date and Time:
Summary:
- IL-27 is a heterodimeric cytokine consisting of 2 subunits (IL-27p28 and Epstein-Barr virus induced gene 3 (EBI3)) that limits the intensity and duration of T cell-mediated immunity.
- High levels of IL-27p28, EBI3, and IL27RA transcript levels are often elevated in renal cell carcinoma (RCC) tumors and are associated with poor clinical outcome.
- SRF388 inhibits IL-27 signaling, diminishes inhibitory receptor expression and increases cytokine production. This pro-inflammatory response is enhanced when combined with PD-1 blockade.
- Data from these studies indicate that blockade of IL-27 can potentiate anti-tumor responses by counteracting IL-27-mediated immune escape.
Presentation Type: e-poster (Abstract: 4548)
Title: SRF813, a fully human monoclonal antibody targeting the inhibitory receptor CD112R, enhances immune cell activation and anti-CD112R treatment in vivo demonstrates preclinical anti-tumor activity
Lead Author:
Date and Time:
Summary:
- SRF813 inhibits the CD112-CD112R interaction and enhances NK cell activation.
- CD112R inhibition in mouse tumor models reduced tumor growth and increased tumor-infiltrating lymphocyte activation.
- The combination of anti-CD112R with PD-1 blockade leads to greater tumor growth inhibition than either treatment alone.
- These preclinical data demonstrate that CD112R is a negative regulator of immune responses and that CD112R inhibition can potentiate anti-tumor responses in cancers that express CD112.
Presentation Type: e-poster (Abstract: 2196)
Title: SRF231, a fully human CD47 antibody, potentiates the effects of opsonizing antibodies and cytotoxic chemotherapies in preclinical cancer models
Lead Author:
Date and Time:
Summary:
- SRF231 demonstrates anti-tumor activity as a monotherapy in multiple myeloma (MM) and non-small cell lung cancer (NSCLC) models.
- SRF231 potentiates the effects of opsonizing antibodies (elotuzumab and daratumumab) in preclinical MM xenograft models.
- SRF231 potentiates the effects of taxane and platinum-based standard of care chemotherapies in preclinical NSCLC xenograft models.
Presentation Type: e-poster (Abstract: 4515)
Title: The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer
Lead Author:
Date and Time:
Summary:
- Anti-CD47 directed therapy with SRF231 demonstrates the ability to significantly increase the anti-tumor activity of standard chemotherapies in xenograft and platinum-resistant patient-derived xenograft (PDX) models of ovarian cancer.
In 2018,
About Surface Oncology:
Contacts:
Investors
matt@gilmartinir.com
617-901-7698
Media
tom@tenbridgecommunications.com
857-559-3397
Source:
2020 GlobeNewswire, Inc., source